Willow vs Embody: Price, support, shipping, and meds compared
Quick verdict: For patients focused on structured follow-up and digital progress tracking choose Willow; for price-sensitive patients who want fast, low-cost compounded semaglutide or tirzepatide and quick delivery choose Embody.
Explore Willow’s structured program
Willow vs Embody at a glance
This comparison of Willow vs Embody highlights five key differences supported by captured evidence: starting price, program features and follow-up, medication type and regulatory notes, shipping and delivery, and ideal user fit. Both operate by telehealth clinicians and provide medication only when a licensed clinician determines it is medically appropriate or after clinician review.
Direct comparison table
| Criteria | Willow | Embody |
|---|---|---|
| Starting price | $299 starting price reported | $69/month semaglutide; $119/month tirzepatide |
| Program focus | Structured weight management with progress tracking and follow-up | Lean, prescription-forward GLP-1 program without premium add-ons |
| Medication type | Oral GLP-1; compounded medications, when offered, are not FDA-approved | Compounded semaglutide and tirzepatide only; compounded meds are not FDA-approved |
| Shipping and delivery | Captured page did not verify shipping details | Free shipping; arrives in 1-2 days after approval |
| Best for | Users who want structured digital follow-up | Cost-driven patients who want a straightforward, low-cost program |
Price and value: clear gap in entry cost
Willow’s captured starting price is 299 while Embody advertises compounded semaglutide at 69/month and compounded tirzepatide at 119/month. Embody positions $69 semaglutide as a limited-time price cut from $299 and emphasizes flat locked monthly pricing, no membership, and no hidden fees. Willow’s messaging centers on program structure rather than low entry price. If entry cost is the primary concern, Embody is consistently presented as the lower cost option.
Program features and follow-up: tracking versus no-frills
Willow emphasizes a telehealth-first weight management program built as a structured journey. Its features include a licensed telehealth team, progress tracking tools, and follow-up consultations. Willow frames the program as converting GLP-1 efficacy into long-term outcomes through behavioral scaffolding and follow-up. Embody, by contrast, runs a lean model focused on prescription and telemed visits without premium coaching or integrated monitoring. Embody includes clinician review and 24/7 support access for dosing and side-effect questions but lists fewer premium monitoring features.
Compare Willow follow-up tools
Medication type and regulatory notes
Both providers disclose that compounded medications are not FDA-approved finished products. Willow notes that compounded medications, when offered, are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality. Embody explicitly states its compounded semaglutide and tirzepatide are not FDA-approved finished products and that its model prescribes compounded GLP-1s after licensed provider review. Both require clinician review to determine medical appropriateness or to prescribe.
Shipping, delivery, and commitments
Embody advertises free shipping with fast 1-2 day delivery after clinician approval, no monthly membership, and cancel anytime. Willow’s captured page did not verify shipping, membership, or cancellation details. The presence of fast free delivery is a distinguishing operational difference in the evidence set.
Who each provider is best for
Willow is best for users seeking structured digital follow-up and progress tracking combined with telehealth clinician oversight. Embody is best for cost-driven patients who want straightforward access to compounded semaglutide or tirzepatide, free fast delivery, and lower monthly outlays without premium add-ons.
Check Embody shipping and pricing
Start with Willow’s program overview
Final thoughts on Willow vs Embody
Willow vs Embody boils down to a trade off between structured support and low entry price. Willow highlights progress tracking, a licensed telehealth team, and follow-up consultations as its distinctive strengths. Embody emphasizes aggressive pricing for compounded semaglutide at 69/month and compounded tirzepatide at 119/month, free 1-2 day shipping after approval, and a no-frills telehealth model. Both require licensed clinician review and both note that compounded medications are not FDA-approved finished products.
Choose Willow if…
You want a telehealth-first program that emphasizes structured digital follow-up, progress tracking tools, and follow-up consultations to support long-term weight management.
Choose Embody if…
You are price sensitive and want low-cost compounded semaglutide or tirzepatide with free fast 1-2 day shipping, a lean prescription-forward model, and no long-term membership commitment.